Drug discovery company Insilico Medicine has entered a research collaboration with pharmaceutical giant Eli Lilly to advance AI-driven drug discovery.  Insilico will use its validated Pharma.AI platform to generate, design, and optimise candidate compounds against targets defined under the agreement.   The company is eligible to receive over $100 million including upfront, milestone payments and tiered […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!